SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure amid its boards investigation into CEO Jensen Huangs admitted affair with a businesswoman alleged to have ties to Chinese intelligence, raising speculation about national-security scrutiny and Huangs job security. Traders are split between fearing leadership disruption or further damaging disclosures and viewing the controversy as separate from Nvidias business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A sharp selloff ahead of Hims & Hers Q3 results has traders debating whether the weakness reflects concern about the report or simply volatile positioning; unverified earnings-leak claims are speculation, not confirmed news. Bulls cite the Eli Lilly obesity-drug partnership and growth prospects, while bears focus on potential margin pressure and the outlook.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline alongside a broader crypto selloff has traders focused on whether it will break below the $1 level, with some attributing pressure to market liquidations and uncertainty around crypto regulation and the CLARITY Act. Bearish calls for further losses and frustration over XRPs weak performance compete with holders buying the dip and arguing the token is near a bottom.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is being tied to an Oppenheimer upgrade and Googles use of AMD EPYC processors in its new AI infrastructure, reinforcing the companys data-center growth story. Traders also speculate that Nvidias CEO controversy is prompting a rotation into AMD, though some question the valuation and warn the sharp move could fade.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp, high-volume run-up ahead of Trade Desks Q3 earnings has put the report in focus, with traders speculating about short covering and an unverified earnings leak. Bulls see room for a rebound, while skeptics warn that weak ad-growth expectations could erase the gains and question whether to hold through the release.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

A sharp rally in small caps has put IWM in focus, with traders attributing the move to a possible short squeeze and rotation into the Russell 2000. Bulls welcome the momentum, while skeptics question the rallys light volume and weak inflows and warn it may fade; CPI and Iran-deal speculation add uncertainty.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Twos earnings report ahead of the scheduled GTA VI launch is driving attention, with traders focused on managements guidance and whether it will provide preorder details. Many expect the blockbuster game and its online monetization to boost the business, while others warn that high expectations may already be priced in and the stock could fall on cautious commentary or a sell-the-news reaction.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

AGLT is drawing attention after a sharp post-merger selloff, with traders blaming typical de-SPAC selling and questioning the companys finances, profitability, and valuation ahead of a financial report. Some see the weakness as a chance to accumulate, citing Agilitys humanoid-robot orders and long-term potential, while others remain bearish on the SPAC and its execution risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI growth drove a third-quarter revenue beat and higher full-year guidance, but the share-price pullback despite the results has fueled a sell the news debate. Traders are also focused on Phase 3 data for a subcutaneous BRIUMVI formulation as a future catalyst.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the Nov. 22 PDUFA date and HOPE-3 upper-limb results. Bulls cite the trial data and support from treating physicians, while skeptics emphasize FDA concerns and the risk of a rejection; whether any approval would also cover cardiac benefits remains debated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Encouraging early data from CRISPRs zugo-cel autoimmune trial and CTX310 cardiovascular study is driving discussion, with traders highlighting responses and lipid reductions alongside a favorable safety profile. The reaction is tempered by the small patient groups and doubts that promising clinical data will translate into a sustained stock move.

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.

VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.

3 Promising Genomics Stocks to Add to Your Portfolio Now 

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Equity

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.


Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Key PointsOne of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted.</li><li>The draft guidance is now open for public comment, which will later be reviewed by the FDA before it decides whether to adopt it.&nbsp;</li><li>Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient.</li></ul>Shares of gene-editing companies, including Prime Medicine (PRME), rallied on Wednesday after the U.S. Food and Drug Administration issued draft guidance designed to speed personalized treatment for rare genetic diseases.Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction. Once clinical results support the core approach, new versions that stay within set limits can be added later using mainly lab tests instead of full new patient trials. The guidance applies to gene-editing therapies for rare diseases caused by a single known genetic fault.Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted. The draft guidance is now open for public comment, which will be later reviewed by the FDA before it decides whether to adopt it.Shares of Prime Medicine were up 20% at the time of writing, while Beam Therapeutics traded 14% higher and Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) climbed 6-11%. CRISPR Therapeutics (CRSP) posted more modest gains of 4%.<h2 class="st-heading-2">Why PRME Is Outperforming Peers</h2>Prime clocked larger gains than its peers as it builds on company-specific updates. Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient. The FDA also granted the program Rare Pediatric Disease designation. Initial clinical data from the Wilson disease study are expected in 2027.The company also recently received the FDA’s clearance to start human trials of an alpha-1 antitrypsin deficiency candidate.<h2 class="st-heading-2">How Did PRME Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$PRME" data-symbol-id="PRME" href="https://stocktwits.com/symbol/PRME" target="_blank">PRME stock</a> jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume increased from 'low' to 'extremely high' levels.A Stocktwits user noted that big pharma company Bristol Myers Squibb is invested in Prime. The user is referring to a collaboration deal between BMY and Prime inked in Sept. 2024 under which Prime received $110 million upfront, including a $55 million equity investment. The company is eligible for more than $3.5 billion in potential milestones under the deal.<stembedurl>https://stocktwits.com/Cello69/message/667555201</stembedurl>Another user, however, warned of upcoming dilution.<stembedurl>https://stocktwits.com/Regard994/message/667538755</stembedurl>PRME stock has gained 51% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-hits-fresh-52-week-low-ahead-of-earnings-as-robotaxi-fears-linger/cZU9V5OR9GK">UBER Stock Hits Fresh 52-Week Low Ahead Of Earnings As Robotaxi Fears Linger</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artwork of DNA Editing. Source: Getty Images

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.

Beam Therapeutics Inc

Editas Medicine Inc

Intellia Therapeutics Inc

Prime Medicine Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRSP News